Literature DB >> 11857293

The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients.

Meinoshin Okumura1, Mitsunori Ohta, Hisashi Tateyama, Katsuhiro Nakagawa, Akihide Matsumura, Hajime Maeda, Hiroto Tada, Tadaaki Eimoto, Hikaru Matsuda, Akira Masaoka.   

Abstract

BACKGROUND: Although the histologic classification of thymic epithelial tumors has been confusing and controversial, an agreement on the universal classification system for thymic epithelial tumors was achieved by the World Health Organization (WHO) in 1999. The authors previously reported that the WHO histologic classification system reflects invasiveness and immunologic function of thymic epithelial tumors. In this subsequent study, they examined the prognostic significance of this classification system.
METHODS: Clinical features as well as postoperative survival of patients with thymoma, but not thymic carcinoma, were examined with reference to WHO histologic classification based on an experience with 273 patients over a 44-year period.
RESULTS: There were 18 type A tumors, 77 type AB tumors, 55 type B1 tumors, 97 type B2 tumors, and 26 type B3 tumors. In patients with type A, AB, B1, B2, and B3 tumors, the respective proportions of invasive tumor were 11.1%, 41.6%, 47.3%, 69.1%, and 84.6%; the respective proportions of tumors with involvement of the great vessels were 0%, 3.9%, 7.3%, 17.5%, and 19.2%; and the respective 20-year survival rates were 100%, 87%, 91%, 59%, and 36%. According to the Masaoka staging system, the 20-year survival rates were 89%, 91%, 49%, 0%, and 0% in patients with Stage I, II, III, IVa, and IVb disease, respectively. By multivariate analysis, the Masaoka staging system and the WHO histologic classification system were significant independent prognostic factors, whereas age, gender, association with myasthenia gravis, completeness of resection, or involvement of the great vessels were not significant independent prognostic factors.
CONCLUSIONS: This study showed that histologic appearance reflects the oncologic behavior of thymoma when the WHO classification system is adopted. The WHO classification system may be helpful in clinical practice for the assessment and treatment of patients with thymoma. Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10225

Entities:  

Mesh:

Year:  2002        PMID: 11857293     DOI: 10.1002/cncr.10226

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  147 in total

1.  Circulating miR-21-5p and miR-148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors.

Authors:  Teresa Bellissimo; Emanuele Russo; Federica Ganci; Carmen Vico; Andrea Sacconi; Flavia Longo; Domenico Vitolo; Marco Anile; Daniele Disio; Mirella Marino; Giovanni Blandino; Federico Venuta; Francesco Fazi
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

2.  (18)F-FDG PET for the evaluation of thymic epithelial tumors: Correlation with the World Health Organization classification in addition to dual-time-point imaging.

Authors:  Atsuo Inoue; Noriyuki Tomiyama; Mitsuaki Tatsumi; Naoki Ikeda; Meinoshin Okumura; Hiroyuki Shiono; Masayoshi Inoue; Ichiro Higuchi; Katsuyuki Aozasa; Takeshi Johkoh; Hironobu Nakamura; Jun Hatazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-14       Impact factor: 9.236

3.  MR imaging of thymic epithelial tumors: correlation with World Health Organization classification.

Authors:  Atsuo Inoue; Noriyuki Tomiyama; Kiminori Fujimoto; Junko Sadohara; Itsuko Nakamichi; Yasuhiko Tomita; Katsuyuki Aozasa; Mitsuko Tsubamoto; Sachiko Murai; Javzandulam Natsag; Hiromitsu Sumikawa; Naoki Mihara; Osamu Honda; Seiki Hamada; Takeshi Johkoh; Hironobu Nakamura
Journal:  Radiat Med       Date:  2006-04

4.  Texture analysis of 18F-FDG PET/CT for grading thymic epithelial tumours: usefulness of combining SUV and texture parameters.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Tetsuya Shinaji; Masayuki Nakajo; Masaya Aoki; Atsushi Tani; Masami Sato; Takashi Yoshiura
Journal:  Br J Radiol       Date:  2018-01-19       Impact factor: 3.039

5.  Prognostic stratification of thymic epithelial tumors based on both Masaoka-Koga stage and WHO classification systems.

Authors:  Geun Dong Lee; Hyeong Ryul Kim; Se Hoon Choi; Yong-Hee Kim; Dong Kwan Kim; Seung-Il Park
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

Review 6.  Pediatric thymomas: report of two cases and comprehensive review of the literature.

Authors:  Annabelle L Fonseca; Doruk E Ozgediz; Emily R Christison-Lagay; Frank C Detterbeck; Michael G Caty
Journal:  Pediatr Surg Int       Date:  2013-12-10       Impact factor: 1.827

7.  Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.

Authors:  Thomas Neuhaus; Joachim Luyken
Journal:  Target Oncol       Date:  2012-10-23       Impact factor: 4.493

8.  Thymic neoplasm: a rare disease with a complex clinical presentation.

Authors:  Omar M Rashid; Anthony D Cassano; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

9.  Thymoma associated with myasthenia gravis in infancy.

Authors:  J B Ghosh; Mahua Roy; Tanushree Peters
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

10.  Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry.

Authors:  Bryan M Burt; Xiaopan Yao; Joseph Shrager; Alberto Antonicelli; Sukhmani Padda; Jonathan Reiss; Heather Wakelee; Stacey Su; James Huang; Walter Scott
Journal:  J Thorac Oncol       Date:  2016-08-24       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.